Last reviewed · How we verify

DHEA (0.25%) — Competitive Intelligence Brief

DHEA (0.25%) (DHEA (0.25%)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy / Prohormone. Area: Women's Health / Gynecology.

phase 3 Hormone replacement therapy / Prohormone Estrogen receptor, Androgen receptor (via local conversion) Women's Health / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

DHEA (0.25%) (DHEA (0.25%)) — EndoCeutics Inc.. DHEA (dehydroepiandrosterone) is a prohormone that is converted to estrogen and testosterone in peripheral tissues, restoring hormone levels in postmenopausal women.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DHEA (0.25%) TARGET DHEA (0.25%) EndoCeutics Inc. phase 3 Hormone replacement therapy / Prohormone Estrogen receptor, Androgen receptor (via local conversion)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy / Prohormone class)

  1. EndoCeutics Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DHEA (0.25%) — Competitive Intelligence Brief. https://druglandscape.com/ci/dhea-0-25. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: